Novo Nordisk Pharmatech Showcases Recombinant Insulin at BioProcess International Conference and Exhibition
Novo Nordisk Pharmatech has announced it will be attending the BioProcess International conference and exhibition.
To be held from 25 September to 28 September at the Hynes Convention Center in Boston, Massachusetts, the conference is the largest exhibition devoted to biomanufacturing and brings you the science, technologies, and partners needed to accelerate promising biologics towards commercial success.
Novo Nordisk Pharmatech invites you to visit booth 1030 to discover its recombinant insulin for innovative biologics and pharmaceutical grade quaternary ammonium compounds.
The company is one of the leading worldwide suppliers of recombinant insulin and its products are key components in serum-free growth media for mammalian cells. They are approved by regulatory bodies worldwide, including the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and manufactured to current good manufacturing practices (cGMP) standards, which guarantees:
- Global regulatory compliance
- Consistent high quality
- Extensive regulatory documentation
- Continuous availability
- Secure global supply chain
- High levels of service and support
Novo Nordisk Pharmatech delivers a proven record of product purity, reliability, and consistency. It can even tailor quality products for future therapies.